Testosterone deficiency may be associated with a broad range of signs and symptoms * 1, 2
Testosterone deficiency may be associated with a broad range of signs and symptoms * 1, 2
*
� Depressed mood, impaired cognition, irritability
� Diminished energy, sense of vitality, or sense of well-being
� Sleep disturbances
� Diminished muscle mass and strength
� Decreased bone density
� Increased visceral fat
� Decrease in body hair and skin alterations
� Anaemia
� Increased fatigue
� Erectile dysfunction( ED)
� Diminished libido
� Difficulty achieving orgasm
Adapted from Rhoden et al, 20042 and Nieschlag et al, 20063.
� Only 10 – 30 % of men with Klinefelter’ s are diagnosed clinically during their lifetime 3
Diagnosis of testosterone deficiency should be made only in men with consistent symptoms and signs and unequivocally low serum testosterone levels. 4
Reandron ® 1000 Minimum Product Information) Reandron 1000( testosterone undecanoate) 1000 mg / 4 mL, solution for injection. Indication: Testosterone replacement in primary and secondary male hypogonadism. Dose: 1 ampoule injected i. m every 10-14 weeks into gluteal muscle. The first injection interval may be reduced to a minimum of 6 weeks to achieve steady-state testosterone levels more rapidly. Contraindications: Androgen-dependent prostate / breast carcinoma, hypercalcaemia accompanying malignant tumours, hypersensitivity to testosterone undecanoate or the excipients, past or present liver tumours, use in women. Precautions: Regular prostate / breast and haemoglobin / haematocrit monitoring. Patients with diabetes, bleeding or coagulation disorder, predisposed to oedema, hypertension, epilepsy or migraine, severe cardiac / hepatic / renal insufficiency. Potentiation of pre-existing sleep apnoea. Effect on doping tests. Inject strictly i. m and very slowly to avoid pulmonary oily microembolism. Interactions: Hypoglycaemic agents, inducers of microsomal enzymes( e. g. barbiturates), oxyphenabutazone, cyclosporin, oral anticoagulants, thyroid laboratory tests. Adverse Effects: Polycythaemia, weight increased, acne, PSA increased, prostate examination abnormal, benign prostate hyperplasia, hot flush, various kinds of injection site reactions, suspected anaphylactic reactions. For other events refer to full PI. Minimum PI last updated 28 April 2011. References: 1. Rhoden EL & Morgentaler A. Risks of Testosterone-Replacement Therapy and Recommendations for Monitoring. N Engl J Med 2004; 350( 5): 482 – 92. 2. Nieschlag E et al. Investigation, Treatment, and Monitoring of Late-Onset Hypogonadism in Males: ISA, ISSAM, and EAU Recommendations. J Androl. 3. Handelsman DJ & Zajac JD. Androgen deficiency and replacement therapy in men. Med J Aust 2004; 180 529 – 35. 4. Bhasin S et al. Testosterone Therapy in Men with Androgen Deficiency Syndromes: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab, June 2010, 95( 6): 2536 – 2559. 2006, 27( 2): 135 – 7.
Please review full Product Information before prescribing. Full Product information is available from Bayer Australia Ltd.
Bayer Australia Ltd. ABN 22 000 138 714, 875 Pacific Highway, Pymble NSW 2073. ® Registered Trademark of Bayer AG, Germany. L. AU. WH. 03.2013.0351. March 2013.
PBS Information: Authority required. Refer to PBS Schedule for full information.
46 46 medicalforum